Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea

ConclusionsIntravenous ferric carboxymaltose (1,000 mg) monotherapy increases hemoglobin levels without serious adverse events in patients with cancer. Hepcidin is a useful biomarker for predicting iron requirement in cancer patients. Trial registrationClinicaltrials.gov NCT02599012

Source: PLoS Medicine - June 7, 2020 Category: Internal Medicine Authors: Jun Ho Jang Source Type: research